INUV vs CDLX

For growth investors, Inuvo, Inc.

(INUV) is the stronger pick with 2. 9% revenue growth year-over-year, versus -16. 2% for Cardlytics, Inc. (CDLX). The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Inuvo, Inc.

(INUV) delivered a total return of -74. 2%, compared to -99. 2% for Cardlytics, Inc. (CDLX). Over 10 years, the gap is even starker: INUV returned -89. 7% versus CDLX's -94. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Inuvo, Inc.

(INUV) is the lower-risk stock at 1. 66β versus Cardlytics, Inc. 's 3. 18β — meaning CDLX is approximately 92% more volatile than INUV relative to the S&P 500.

By revenue growth (latest reported year), Inuvo, Inc.

(INUV) is pulling ahead at 2. 9% versus -16. 2% for Cardlytics, Inc. (CDLX). On earnings-per-share growth, the picture is similar: Cardlytics, Inc. grew EPS 50. 1% year-over-year, compared to 31. 7% for Inuvo, Inc.. Over a 3-year CAGR, INUV leads at 4. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Inuvo, Inc.

(INUV) is the more profitable company, earning -5. 9% net margin versus -44. 4% for Cardlytics, Inc. — meaning it keeps -5. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INUV leads at -7. 8% versus -20. 2% for CDLX. At the gross margin level — before operating expenses — INUV leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Inuvo, Inc.

(INUV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Cardlytics, Inc. (CDLX) carries a higher beta of 3. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INUV: -89. 7%, CDLX: -94. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Communication Services sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.